Inovio Pharmaceuticals, Inc.

INO

Healthcare Biotechnology

Inovio Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $65,300.00, down 70.0% from fiscal 2024.

Revenue
−83.2%
EPS
+88.5%
Free cash flow
+13.4%

Quarter to June 2026, against a year earlier

1.22 0.23 −15.86%
Market cap
$125.6M
P/E
n/m
Fwd P/E
n/m
Dividend yield
—
F-score
1/9
ROIC
0.00%
Net debt / EBITDA
0.7×
Dividend safety
n/a
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Piotroski F-Score
1 2 4 2 2 3 2 2 4 2
P/E ratio
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
P/S ratio
211.46 70.12 180.43 35.34 587.16 185.17 79.19 12.14 9.06 14.63
Altman Z-Score
(36.80) (23.34) (13.77) (5.96) 2.00 8.33 (7.78) (3.24) 0.02 1.86
Altman Z″-Score (non-manufacturers)
(85.44) (51.27) (30.07) (13.11) (2.61) 4.36 (19.06) (15.55) (5.16) (5.49)
P/FCF ratio
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
P/Operating CF
(4.21) (2.53) (5.71) (9.98) (27.50) (26.79) (23.70) (21.41) (27.43) (34.72)
Beneish M-Score
— (2.51) (3.11) 0.10 (4.47) 2.28 (3.03) (3.82) (3.52) (1.60)
P/B ratio
3.39 0.73 1.28 1.63 2.61 2.98 60.25 4.25 2.68 4.19
EV/Sales
102.86 (39.21) 25.77 12.31 369.46 132.14 76.15 9.47 6.04 11.67
EV/EBITDA
0.00 0.25 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EV/FCF
(0.45) 0.27 (0.18) (0.58) (3.03) (5.48) (3.19) (3.86) (3.51) (6.30)
Current Ratio
1.40 2.77 3.60 3.25 6.82 11.30 2.94 2.49 3.91 2.84
Net Debt/EBITDA
0.70 0.85 1.14 0.90 1.31 3.29 0.12 0.91 1.60 1.44
Debt/Equity
0.00 0.00 0.00 0.07 0.04 0.04 14.25 0.00 0.00 0.00
ROE
(183.47%) (115.42%) (79.55%) (89.97%) (70.55%) (71.34%) (258.25%) (84.50%) (66.35%) (49.27%)
ROA
(90.61%) (75.49%) (52.02%) (66.27%) (58.64%) (48.68%) (86.79%) (60.92%) (48.87%) (38.05%)
ROIC
0.00% 0.00% 0.00% 0.00% (1,413.97%) (113.79%) 0.00% (1,013.93%) (347.05%) (256.00%)
Return on Tangible Assets
(425.11%) (162.10%) (116.98%) (123.76%) (75.88%) (37.75%) (159.18%) (141.63%) (72.73%) (82.12%)
Average Days of Receivables
0.00 2,009.51 1,055.17 417.49 1,651.84 938.89 180.38 48.55 56.11 171.00
Earnings Yield
(110.63%) (220.54%) (90.39%) (77.66%) (29.07%) (12.55%) (36.68%) (26.01%) (22.87%) (14.15%)
Free Cash Flow Yield
(108.01%) (208.64%) (78.38%) (59.84%) (20.74%) (13.02%) (30.11%) (20.23%) (19.00%) (12.66%)
Free Cash Flow per Share
(1.90) (3.85) (5.34) (10.92) (12.47) (13.89) (12.02) (9.81) (10.64) (10.74)
Book value per Share
0.51 2.52 5.29 11.18 22.97 35.69 0.66 11.29 20.92 20.23
Free Cash Flow
(88.92) (104.51) (118.47) (217.18) (216.94) (179.50) (98.84) (75.64) (72.50) (65.49)
EV/EBIT
0.00 0.25 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Other line items

Show all line items

Columns are period end dates · fundamentals updated 26 Oct 2026